Healios (Drug Discovery) Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
82
- Stock Symbol
-
4593
- Investments
-
3
- Share Price
-
$1.24
- (As of Friday Closing)
Healios (Drug Discovery) General Information
Description
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
Contact Information
Website
www.healios.co.jpCorporate Office
- 15th Floor, Toranomon Hills Business Tower
- 1-17-1 Toranomon, Minato-ku
- Tokyo, 100-0006
- Japan
Corporate Office
- 15th Floor, Toranomon Hills Business Tower
- 1-17-1 Toranomon, Minato-ku
- Tokyo, 100-0006
- Japan
Healios (Drug Discovery) Timeline
Healios (Drug Discovery) Stock Performance
As of 20-Nov-2026, Healios (Drug Discovery)’s stock price is $1.24. Its current market cap is $167M with 135M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.24 | $1.32 | $1.20 - $3.19 | $167M | 135M | 1.74M | -$0.10 |
Healios (Drug Discovery) Financials Summary
As of 30-Sep-2026, Healios (Drug Discovery) has a trailing 12-month revenue of $299K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 203,160 | 177,986 | 85,616 | 69,489 |
| Revenue | 299 | 695 | 3,698 | 861 |
| EBITDA | (29,311) | (20,485) | (16,824) | (22,447) |
| Net Income | (16,603) | (14,813) | (27,963) | (27,208) |
| Total Assets | 145,036 | 109,022 | 90,371 | 107,459 |
| Total Debt | 23,625 | 16,698 | 16,959 | 32,135 |
Healios (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Healios (Drug Discovery) Comparisons
Industry
Financing
Details
Healios (Drug Discovery) Competitors (1)
One of Healios (Drug Discovery)’s competitors is MindMaze Therapeutics Holding, a Formerly PE-Backed company based in Geneva, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MindMaze Therapeutics Holding | Formerly PE-Backed | Geneva, Switzerland |
Healios (Drug Discovery) Patents
Healios (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-7909737-B1 | Apparatus for absorbent articles | Active | 25-Nov-2025 | ||
| EP-4756013-A1 | Method for producing natural killer cells | Pending | 02-Aug-2023 | ||
| WO-2025028596-A1 | Method for producing natural killer cells | Inactive | 02-Aug-2023 | ||
| JP-2026502608-A | Cryogenic storage device and method | Pending | 16-Jan-2023 | ||
| EP-4652419-A1 | Cryostorage devices and methods | Pending | 16-Jan-2023 | F25D29/001 |
Healios (Drug Discovery) Signals
Healios (Drug Discovery) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Healios (Drug Discovery) Investments & Acquisitions (3)
Healios (Drug Discovery)’s most recent deal was a Merger/Acquisition with Athersys for . The deal was made on 04-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Athersys | 04-Apr-2024 | Merger/Acquisition | Biotechnology | ||
| Athersys | 30-Apr-2018 | PIPE | Biotechnology | ||
| Sighregen | 28-Feb-2014 | Joint Venture | Drug Discovery |
Healios (Drug Discovery) ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.7 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Healios (Drug Discovery) Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Athersys | Cleveland, OH | 1995 |
Healios (Drug Discovery) FAQs
-
When was Healios (Drug Discovery) founded?
Healios (Drug Discovery) was founded in 2011.
-
Where is Healios (Drug Discovery) headquartered?
Healios (Drug Discovery) is headquartered in Tokyo, Japan.
-
What is the size of Healios (Drug Discovery)?
Healios (Drug Discovery) has 82 total employees.
-
What industry is Healios (Drug Discovery) in?
Healios (Drug Discovery)’s primary industry is Drug Discovery.
-
Is Healios (Drug Discovery) a private or public company?
Healios (Drug Discovery) is a Public company.
-
What is Healios (Drug Discovery)’s stock symbol?
The ticker symbol for Healios (Drug Discovery) is 4593.
-
What is the current stock price of Healios (Drug Discovery)?
As of 20-Nov-2026 the stock price of Healios (Drug Discovery) is $1.24.
-
What is the current market cap of Healios (Drug Discovery)?
The current market capitalization of Healios (Drug Discovery) is $167M.
-
What is Healios (Drug Discovery)’s current revenue?
The trailing twelve month revenue for Healios (Drug Discovery) is $299K.
-
Who are Healios (Drug Discovery)’s competitors?
MindMaze Therapeutics Holding is a competitor of Healios (Drug Discovery).
-
What is Healios (Drug Discovery)’s annual earnings per share (EPS)?
Healios (Drug Discovery)’s EPS for 12 months was -$0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process